Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Second-Quarter Results

Last week, you might have seen that Mankind Pharma Limited (NSE:MANKIND) released its quarterly result to the market. The early response was not positive, with shares down 5.1% to ₹2,262 in the past week. The result was positive overall - although revenues of ₹37b were in line with what the analysts predicted, Mankind Pharma surprised by delivering a statutory profit of ₹12.38 per share, modestly greater than expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from Mankind Pharma's 16 analysts is for revenues of ₹146.2b in 2026. This would reflect a satisfactory 7.9% increase on its revenue over the past 12 months. Per-share earnings are expected to expand 15% to ₹48.53. Before this earnings report, the analysts had been forecasting revenues of ₹147.4b and earnings per share (EPS) of ₹50.36 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.

View our latest analysis for Mankind Pharma

It might be a surprise to learn that the consensus price target was broadly unchanged at ₹2,726, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Mankind Pharma at ₹3,300 per share, while the most bearish prices it at ₹2,150. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Mankind Pharma'shistorical trends, as the 17% annualised revenue growth to the end of 2026 is roughly in line with the 17% annual growth over the past three years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 10% annually. So it's pretty clear that Mankind Pharma is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Mankind Pharma analysts - going out to 2028, and you can see them free on our platform here.

Even so, be aware that Mankind Pharma is showing 1 warning sign in our investment analysis , you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.